Bio-Rad's Q2 Revenues Jump 9 Percent on Strong Dx Sales | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bio-Rad reported after the close of the market Tuesday that its second-quarter revenues increased around 9 percent, with double-digit growth for its clinical diagnostics business offsetting slow growth for its life science segment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.